Apogee Therapeutics Inc. (APGE)
(Delayed Data from NSDQ)
$45.64 USD
-0.72 (-1.55%)
Updated May 31, 2024 04:00 PM ET
After-Market: $45.72 +0.08 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
APGE 45.64 -0.72(-1.55%)
Will APGE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for APGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APGE
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
APGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for APGE
Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market
Apogee Therapeutics Welcomes Dr. Bollinger to Board
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
Apogee Therapeutics expands board of directors with appointment of Bollinger
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo